Women's Guide to Research Compounds: Peptides & Nootropics

Women's physiology differs from men's in ways that directly impact how compounds are absorbed, metabolized, and cleared. Lower average body weight means weight-based dosing often results in a lower absolute dose. Higher body fat percentages affect the distribution of lipophilic compounds. And critically, fluctuating estrogen and progesterone levels across the menstrual cycle can modulate receptor sensitivity, enzyme activity, and even blood-brain barrier permeability.

These differences don't make research compounds more dangerous for women — they just mean that protocols designed with a 180 lb male in mind may not be optimal. Starting at the lower end of dose ranges, monitoring responses across your cycle, and adjusting based on subjective effects is the smart approach. Some women find that compounds like adaptogens (Ashwagandha, Rhodiola) work differently depending on their cycle phase.

Absolute contraindication: All research peptides and most nootropic compounds should be avoided entirely during pregnancy and breastfeeding. No exceptions. There is insufficient safety data, and the potential risks to fetal and infant development are not worth any perceived benefit.

Pregnancy & Breastfeeding

Do NOT use any research peptides or nootropic compounds during pregnancy or breastfeeding. This is a blanket safety recommendation — not compound-specific.

Compounds like BPC-157, Semax, GHK-Cu, and all injectable peptides have not been studied for safety in pregnancy or lactation. The same applies to most nootropics beyond basic vitamins and minerals. If you are pregnant, planning pregnancy, or breastfeeding, discontinue all research compounds and consult your healthcare provider.